Steven K. Galson, M.D., M.P.H., is Senior Vice President for Global Regulatory Affairs and Safety at Amgen. From September, 2010 until May 2014 he was Vice President for Global Regulatory Affairs at Amgen. Prior to this, he was the Senior Vice President for Civilian Health Operations and Chief Health Scientist at Science Applications International Corporation and a consultant for Warburg Pincus. In October 2009, he completed 23 years of government service, most recently - for two years - as Acting Surgeon General of the United States. From January – September 2009 he was also the Acting Assistant Secretary for Health. As Acting Surgeon General Galson launched the Healthy Youth for a Healthy Future Initiative in 2008, which brought national attention to the complex issue of childhood obesity prevention, and prompted hundreds of community-based actions. This initiative included visiting 38 states and personally modeling healthy behaviors directly with children. Dr. Galson also convened, with the NIH, the Surgeon General’s Workshop on pre-term birth in 2008, to jump-start national activities to reduce the incidence of these births. In addition, Galson published two Surgeon General’s Calls to Action: on Deep Vein Thrombosis and Pulmonary Embolism, to bring renewed attention and prevention efforts to a health problem that kills more than 100,000 Americans every year; and on how to Promote Healthy Homes, to bring attention to the connection between housing and health and outline a blueprint for national action. RADM Galson furthered the nation’s evolution toward personalized medicine by releasing a new My Family Health Portrait, a web-based tool to enable individuals and families to create, store and share their family health histories. He also highlighted the importance of preventing underage drinking, by visiting states to encourage local efforts on this persistent challenge. Galson created the Surgeon General’s Perspectives, a column in the journal Public Health Reports, and published eight columns on various prevention topics, bringing a leadership viewpoint to this widely read publication. In addition, RADM Galson started a regular column for dieticians in the Journal of the American Dietetics Association, and published six columns on topics of interest to this key professional organization. Between Jan. and June 2009, as Acting Assistant Secretary of Health, RADM Galson led a Department-wide effort to prepare a plan for the $650 million Prevention and Wellness section of the American Recovery and Reinvestment Act of 2009 and managed 12 core public health programs for HHS. Previously, he served as Deputy Director and Director of the FDA’s Center for Drug Evaluation and Research (CDER) from May 2001 until September 2007, where he provided leadership for the center’s broad national and international programs in pharmaceutical regulation. Dr. Galson began his Public Health Service (PHS) career as an epidemiological investigator at CDC after completing a residency in internal medicine at the Hospitals of the Medical College of Pennsylvania. He has held senior-level positions at the Environmental Protection Agency (EPA); the Department of Energy, where he was Chief Medical Officer; and the Department of Health and Human Services. Prior to his arrival at FDA, he was Director of the EPA’s Office of Science Coordination and Policy, Office of Prevention, Pesticides and Toxic Substances, at the EPA. Dr. Galson is the recipient of numerous awards, including the Surgeon General’s Medallion, three Secretary of Energy Gold Awards and The Founders Medal from the Association of Military Surgeons of the United States. Dr. Galson has been a board member of the National Board of Medical Examiners, a Regent of the Uniformed Services University of Health Sciences and a peer reviewer for medical journals. He holds a BS from Stony Brook University, an MD from Mt. Sinai School of Medicine, and an MPH from the Harvard School of Public Health and is board certified in preventive medicine and public health and occupational medicine. Dr. Galson is currently Professor-at-Large at the Keck Graduate Institute of Applied Life Science, and a Member of the Board of Directors of Vanda Pharmaceuticals.